Tesamorelin

Overview

Tesamorelin was approved by the FDA in 2010 (originally under the brand Egrifta, now available as Egrifta WR) for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy, and it remains an actively prescribed, pharmacy-dispensed medication in the United States, manufactured by Theratechnologies. Separately, tesamorelin acetate is also manufactured and sold as a research-use-only (RUO) compound for laboratories studying GHRH receptor pharmacology, peptide stability, and the growth hormone axis. Helix Bio's product is the RUO research compound, not the approved pharmaceutical.

Composition

Tesamorelin consists of the 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid group attached to the N-terminal tyrosine residue — a modification designed, per the compound's published pharmacology, to slow enzymatic degradation compared with unmodified GHRH fragments. Helix Bio's tesamorelin is supplied as the acetate salt, in lyophilized powder form. The free-base compound is identified by CAS number 218949-48-5 (acetate salt: CAS 901758-09-6), with a molecular formula of C221H366N72O67S and a free-base molecular weight of approximately 5,135.9 g/mol.

Purpose and Intended Use

This product exists to support in vitro and in vivo laboratory research into GHRH receptor signaling, peptide stability engineering, and endocrine regulation. It is manufactured for controlled research settings and is not formulated, tested, or approved by Helix Bio for therapeutic, diagnostic, cosmetic, or any other human or veterinary use.

Product Highlights

• Lyophilized tesamorelin acetate, a stabilized 44-amino-acid GHRH analog
• Identified by CAS 218949-48-5 (free base) with documented molecular formula and sequence
• Packaged specifically for laboratory and institutional research use
• Shipped within the United States
• Supplied strictly on a research-use-only basis, distinct from the FDA-approved pharmaceutical form

Key Features

• Structurally modified sequence — the hexenoyl modification is the defining structural feature researchers reference when comparing tesamorelin to unmodified GHRH analogs like sermorelin
• Acetate salt form — the standard form used across peptide research literature for solubility and stability comparisons
• Lyophilized format — freeze-dried powder supports stability during shipping and cold storage prior to use
• Documented identifiers: CAS number, molecular formula, and molecular weight provided for research recordkeeping
• Research-only distribution — sold exclusively for laboratory, institutional, and academic research applications, not the prescription pharmaceutical

Why Choose This Product

Researchers comparing tesamorelin sources are usually weighing documentation and sourcing transparency, not marketing claims. Helix Bio's listing is built around a clearly identified compound (CAS 218949-48-5), a stated acetate salt form, and packaging built for laboratory handling rather than consumer retail. Because tesamorelin already has a well-documented FDA-approved reference product, researchers have an unusually clear benchmark to compare purity and identity claims against — which makes accurate, unembellished specification data more valuable here than in categories without an approved reference compound.

Who This Product Is For

• Research laboratories and biotechnology companies
• Academic and university research institutions
• Qualified researchers and laboratory professionals purchasing on behalf of an institution

This product is not intended for individual consumers, is not a supplement or over-the-counter product, and is not a substitute for the FDA-approved pharmaceutical (Egrifta / Egrifta WR), which is available only through a prescription and pharmacy dispensing channel. It is not intended for personal, human, or veterinary use.